Randomised controlled trial of the short-term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-deficit/hyperactivity disorder (CIAO-II) by Asherson, Philip et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Randomised controlled trial of the short-term effects of OROS-
methylphenidate on ADHD symptoms and behavioural outcomes
in young male prisoners with attention-deficit/hyperactivity
disorder (CIAO-II)
Citation for published version:
Asherson, P, Johansson, L, Holland, R, Fahy, T, Forester, A, Howitt, S, Lawrie, S, Strang, J, Young, S,
Landau, S & Thomson, L 2019, 'Randomised controlled trial of the short-term effects of OROS-
methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention-
deficit/hyperactivity disorder (CIAO-II)', Trials, vol. 20, no. 1. https://doi.org/10.1186/s13063-019-3705-9
Digital Object Identifier (DOI):
10.1186/s13063-019-3705-9
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Trials
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 02. Jan. 2020
STUDY PROTOCOL Open Access
Randomised controlled trial of the short-
term effects of OROS-methylphenidate on
ADHD symptoms and behavioural
outcomes in young male prisoners with
attention-deficit/hyperactivity disorder
(CIAO-II)
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Abstract
Background: Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent disorder, seen in 20–30% of
young adult prisoners. Pharmacoepidemiological studies, a small randomised controlled trial and open trial data of
methylphenidate suggest clinically significant reductions in ADHD symptoms, emotional dysregulation, disruptive
behaviour and increased engagement with educational activities. Yet, routine treatment of ADHD in offenders is
not yet established clinical practice. There is continued uncertainty about the clinical response to methylphenidate
(MPH), a first-line treatment for ADHD, in offenders, who often present with an array of complex mental health
problems that may be better explained by states of inattentive, overactive, restless and impulsive behaviours. To
address this problem, we will conduct an efficacy trial to establish the short-term effects of osmotic-controlled
release oral delivery system (OROS)-methylphenidate (Concerta XL), an extended release formulation of MPH, on
ADHD symptoms, emotional dysregulation and behaviour.
Methods: This study is a parallel-arm, randomised, placebo-controlled trial of OROS-MPH on ADHD symptoms,
behaviour and functional outcomes in young male prisoners aged 16–25, meeting Diagnostic and Statistical Manual
of Mental Disorders, fifth edition criteria for ADHD. Participants are randomised to 8 weeks of treatment with OROS-
MPH or placebo, titrated over 5 weeks to balance ADHD symptom improvement against side effects. Two hundred
participants will be recruited with a 1:1 ratio of drug to placebo. The primary outcome is change in level of ADHD
symptoms after 8 weeks of trial medication.
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Discussion: Potential benefits include improvement in ADHD symptoms, emotional dysregulation, attitudes
towards violence and critical incidents and increased engagement with educational and rehabilitation programmes.
Demonstrating the efficacy and safety of MPH on ADHD symptoms and associated impairments may provide the
data needed to develop effective healthcare pathways for a significant group of young offenders. Establishing
efficacy of MPH in this population will provide the foundation needed to establish long-term effectiveness studies
with the potential for demonstrating significant reductions in criminal behaviour and improved health-economic
outcomes.
Trial registration: ISRCTN registry, ISRCTN16827947, 31st May 2016; EudraCT number, 2015-004271-78, 31st May
2016. Last particpant last visit 6 June 2019. Data lock 27 August 2019.
Keywords: Neurodevelopmental disorder, ADHD, OROS-methylphenidate, Prison mental health, Trial
Background
Attention-deficit/hyperactivity disorder (ADHD) is char-
acterised by developmentally inappropriate levels of in-
attentive, hyperactive and impulsive behaviours. The
disorder is often accompanied by symptoms of emotional
instability and leads to clinical and psychosocial impair-
ments culminating in long-term negative outcomes and
comorbid conditions [1]. ADHD affects around 5–7% of
children [2, 3] and 3–4% of adults [4, 5]. Individuals meet-
ing diagnostic criteria for ADHD are found at dispropor-
tionately high rates in prison populations with an
estimated prevalence rate between 20 and 30% in young
offender institutes and prisons [6].
Both the National Institute for Health and Care Excel-
lence (NICE) and the Scottish Intercollegiate Guidelines
Network (SIGN) recommend methylphenidate (MPH) for
treating ADHD with significant impairment in children,
adolescents and young adults [7–9]. Nevertheless, it is un-
common to diagnose and treat ADHD in young adult of-
fenders. The reasons for this are unclear, but concerns
have been expressed that the common occurrence of
mental health, neurodevelopmental and psychosocial
problems might provide a better explanation for impul-
sive, overactive and inattentive states in young offenders,
or might interfere with the treatment response in cases of
ADHD. For these reasons NICE [7] recommended that
drug treatment efficacy trials are needed in offender popu-
lations (page 134 of the full guideline, section 5.18.1.4)
and repeated this recommendation in 2013 [10]. The
guideline stated that ’there should be an assessment of ef-
ficacy in these groups (i.e. forensic and drug abuse popula-
tions) of the ADHD treatments already recommended for
treatment in the community. Randomised controlled trial
design is recommended’. Clinical trials of ADHD treat-
ments have yet to be conducted in young adult offenders,
and the efficacy of MPH treatment for ADHD remains
unknown in this group.
There are two main reasons why response of ADHD
symptoms to stimulant medications may be different for
young offenders compared to responses for previous
studies in community ADHD samples. First, offenders
present with an array of complex mental health prob-
lems that may better explain the states of inattentive,
overactive, restless and impulsive behaviours used to de-
fine ADHD. These include problems commonly seen in
offenders such as personality, anxiety, post-traumatic
stress and substance abuse disorders, in addition to gen-
eral and specific learning difficulties. Second, nearly all
previous treatment trials of ADHD have been conducted
in carefully selected samples with low levels of co-
occurring psychosocial and mental health comorbidities.
However, the co-occurrence of mental health disorders
might modify the efficacy of drug treatments in ADHD.
One example is comorbid drug abuse. Meta-analysis of
treatment trials found no effect of MPH on ADHD
symptoms in ADHD cases comorbid with drug abuse
(standardised mean difference [SMD] = 0.08, p = 0.59),
whereas there was a medium effect in non-comorbid
samples (SMD = 0.51, p < 0.00001) [11]. This may be
relevant to prison populations, where a history of drug
abuse is common. Further, concerns have been
expressed about the potential for stimulant medications
such as MPH to worsen coexisting conditions. The most
recent research recommendations from NICE [8] state
that: ’no evidence was identified to justify different medi-
cation choices in people with ADHD and a history of
psychosis, mania, or personality disorder. These groups
are often excluded from trials. There are reasons (for ex-
ample, mechanism of action of medication options, pre-
vious reports of adverse effects) to suspect that these
groups may respond differently to different drugs, but a
lack of trials to confirm this. Primarily there are some
concerns that stimulant medication may worsen the
symptoms of any of these coexisting conditions’.
Choice of intervention and comparator
To address this problem, we are conducting a randomised
controlled efficacy trial of osmotic-controlled release oral
delivery system methylphenidate (OROS-MPH, Concerta
XL), a sustained release formulation of methylphenidate,
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compared to placebo, in young adult prisoners with
ADHD who are aged between 16 and 25 years.
Previous studies
Previous community studies demonstrate the efficacy of
MPH in reducing ADHD symptoms in children, adoles-
cents and adults with ADHD [12]. A recent comprehen-
sive network meta-analysis estimated an effect size from
randomised controlled trials of MPH in reduction of
ADHD symptoms in adults with an SMD of 0.78 (95%
confidence interval [CI] of 0.62–0.93) [12]. However, there
are only limited trial data for treatment of ADHD in
young offenders presenting with a more complex mix of
psychosocial, mental health and behavioural problems.
One small randomised controlled trial of MPH in a prison
sample of 30 Swedish prisoners with ADHD showed a
large effect (SMD= 2.1) on ADHD symptom reduction
[13]. While this study supports the treatment of ADHD in
offenders, it cannot be considered definitive for the treat-
ment of young offenders more generally, because of the
small sample size, older age group and selection of of-
fenders with severe ADHD and with long-term sentences
treated in a special prison unit in Sweden.
Additional support comes from a pilot open label study
that preceded this protocol; the study investigated the ef-
fects of MPH in 121 young offenders in HMP Isis in
Southeast London who met Diagnostic and Statistical
Manual of Mental Disorders, fifth edition (DSM-5) diag-
nostic criteria for ADHD [14]. That study followed similar
procedures to the protocol reported here, but it was an
open trial with a single treatment arm. Potential partici-
pants were screened using a DSM-IV symptoms checklist,
and diagnosis was confirmed following the DSM-IV-based
Diagnostic Interview for ADHD in Adults (DIVA) and
medical review from a trained consultant psychiatrist. The
prevalence of ADHD in the prison was estimated to be
19%, of which 78% met criteria for the combined type
presentation of ADHD. Significant pre-post treatment re-
ductions, unadjusted for multiple outcome measures, were
seen for investigator-rated ADHD symptoms using the
Conners Adult ADHD Rating Scale (CAARS).
More generally, the benefits of treating ADHD with
MPH are also expected to extend to a wide range of long-
term outcomes relevant to young adult offenders with
ADHD. The evidence for this comes largely from pharma-
coepidemiological studies using within-individual compari-
sons of periods on and off medication, to control for
‘treatment by indication’ effects. For example, suicidal be-
haviour was found to be higher among adults treated for
ADHD with stimulants compared to those who had not
been treated, suggesting that stimulants might increase the
risk of suicidal behaviour [15]. However, reductions in sui-
cidality were found when periods when individuals were
taking medication for ADHD were compared to periods
when the same individuals were not taking medication.
This suggests a protective effective on suicidality during pe-
riods of taking stimulants, although individuals with ADHD
and suicidality are more likely to be treated, presumably be-
cause their ADHD is more severe. Using a similar pharma-
coepidemiological design, a study using Swedish national
registry data of 25,656 male patients with ADHD found a
sixfold higher rate of criminal convictions over a 4-year
period in patients with ADHD compared to controls. Re-
garding medication effects, they found a 32% reduction in
the risk of criminal convictions, using both within and be-
tween methods of analysis, to compare periods on and off
medication for ADHD. Furthermore, these protective ef-
fects on criminal convictions were only seen for ADHD
medications (stimulants or atomoxetine) but not for com-
monly prescribed antidepressants, indicating the specificity
of these findings to ADHD medications [12]. Other out-
comes identified using a similar methodology include vio-
lent reoffending on release from prison [16], depression
[17] and risk of serious transport accidents [18].
In an earlier study of ADHD in prisoners, we found a
sixfold increase in critical incidents among prison in-
mates with high levels of ADHD symptoms compared to
prisoners with low levels of symptoms. This increase
remained significant even after controlling for antisocial
personality disorder [13], thus making this an important
outcome for randomised controlled trials of prisoners
with ADHD. Another important outcome is symptoms
of emotional dysregulation such as irritability, anger and
reactive aggression, which are also commonly seen in of-
fenders with ADHD. Meta-analyses of randomised con-
trolled trials of ADHD medications found reductions in
emotional dysregulation, including problems with tem-
per control, mood lability and emotional over-reactivity
[19, 20]. Hence, treatment of offenders with ADHD
might also lead to significant reductions in emotional
dysregulation and potentially aggressive or violent be-
haviour. The symptoms of ADHD are also known to
interfere with education and employment due to a com-
bination of restlessness, reduced attention span, forget-
fulness and problems with planning and organisation
[21]. Treatment might therefore lead to greater positive
engagement with prison educational and rehabilitation
programmes. In our open label pilot study at HMP Isis,
we also found significant effects on all the secondary
outcomes proposed for this study (all p < 0.001) includ-
ing measures of emotional dysregulation, attitudes to-
wards violence, the number of critical incidents and
positive engagement with the education and rehabilita-
tion programme [14].
Potential benefits
Potential benefits of treating young adult offenders with
ADHD with MPH include improvement in clinical and
Asherson et al. Trials          (2019) 20:663 Page 3 of 21
behavioural outcomes. These include ADHD symptoms,
emotional dysregulation, attitudes towards violence, crit-
ical incidents and engagement with educational and re-
habilitation programmes. Demonstrating efficacy and
safety of MPH on ADHD symptoms and associated im-
pairments may provide the data needed to develop ef-
fective healthcare pathways, including the use of MPH,
for a significant group of young offenders. Establishing
efficacy of MPH in this population will provide the foun-
dation needed to establish long-term effectiveness stud-
ies with the potential for demonstrating significant
reductions in criminal behaviour and improved health-
economic outcomes.
Potential risks
One often-raised concern is the potential for abuse of
prescribed MPH, particularly in a population of of-
fenders with ADHD and high rates of substance abuse.
Stimulants can be abused by crushing short-acting for-
mulations such as immediate release MPH, which can
then be insufflated (snorted) or injected, leading to a
rapid entry of the drug into the brain and the experience
of euphoria. However, when taken orally, the slow phar-
macokinetic profile does not lead to euphoria [22]. This
is important, because it is not possible to crush the trial
medication (OROS-MPH, Concerta XL) or easily extract
MPH for injection. Risk of diversion or abuse is there-
fore reduced in this study using this formulation of
MPH. Furthermore, in our pilot study we did not ob-
serve excessive drug-seeking behaviour for stimulant
medication [14]. The young adult offenders being treated
for ADHD were generally cautious about increasing the
dose of medication and were titrated to modest doses,
comparable to community samples (18% used 18 mg
daily, 37% used 36 mg, 14% used 54mg, 26% used 72 mg
and only 4% used 90mg). There are standard operating
procedures for the delivery of controlled drugs within
the prisons. Other potential risks are the usual range of
adverse effects observed when treating ADHD with
OROS-MPH.
Methods
Trial design
The trial design is a parallel arm, randomised placebo-
controlled trial of an extended release formulation of
MPH (OROS-MPH, Concerta XL) on ADHD symptoms,
behaviour and functional outcomes in young male pris-
oners aged 16–25 who meet DSM-5 criteria for ADHD.
Participants will be randomised to 8 weeks of treatment
with either OROS-MPH or placebo, titrated over 5
weeks to balance ADHD symptom improvement against
side effects. Two hundred participants will be recruited
with a 1:1 ratio of drug to placebo. The duration of each
participant’s follow-up is 8 weeks from the start date of
the trial medication. Figure 1 illustrates the prisoner’s
journey through the trial as the Consolidated Standards
of Reporting Trials (CONSORT) diagram. This process
will be completed following database lock for the trial.
Table 1 is a summary of all trial procedures and assess-
ments. Additional file 2 provides the Standard Protocol
Items: Recommendations for Interventional Trials
(SPIRIT) checklist.
Trial objectives
The primary objective is to establish the efficacy of
OROS-MPH in reducing ADHD symptoms (inattention
and hyperactivity-impulsivity) in young male offenders
aged 16–25 who meet diagnostic criteria for DSM-5
ADHD.
Secondary objectives include evaluating the following:
reductions in emotional dysregulation, the number of
adjudications for antisocial behaviour and rule breaking
in the previous 8 weeks, ratings of aggressive and/or dis-
ruptive behaviour by prison officers and education staff,
attitudes towards violence, self-report of well-being.
Additionally, we intend to investigate the hypothesis
that improvements in secondary behavioural outcomes
are mediated by improvements in ADHD symptoms or
emotional dysregulation.
Study setting
Participants are recruited from two prisons. The first is
HMP & YOI Isis in London (England, UK), a prison for
sentenced young adults and category C offenders, de-
fined as those who cannot be trusted in open conditions
but who are unlikely to try to escape. The second is
HMYOI Polmont in Falkirk (Scotland, UK), a holding fa-
cility for young offenders aged 16–21, with sentences
ranging from 6 months to life. All participants were sen-
tenced prisoners when screened for entry into the trial.
Eligibility criteria
Inclusion criteria
For inclusion into the study, one must be male, aged be-
tween 16 and 25 years (at consent for screening), English
speaking (defined as sufficient to complete study assess-
ments), able to provide informed consent (understand
the information sheet and make an informed decision
taking into account the pros and cons of study participa-
tion) and meeting clinical diagnostic criteria for DSM-5
ADHD.
The diagnostic criteria are defined as five or more symp-
toms of ADHD in either the inattentive or hyperactive-
impulsive symptom domains, and six or more symptoms of
ADHD in either the inattentive or hyperactive-impulsive
symptom domains before the age of 12 years. Where it is
not possible to gain enough clinical information to score
childhood symptoms of ADHD, the operational criteria
Asherson et al. Trials          (2019) 20:663 Page 4 of 21
Fig. 1 CONSORT diagram
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applied have been adapted to include evidence of several
ADHD symptoms with impairment starting before the age
of 12 years, and five or more symptoms currently with
moderate to severe impairment. In addition this includes
persistent trait-like (non-episodic) course of symptoms, im-
pairments in two or more clinical or psychosocial domains
and two or more settings from symptoms of ADHD and
onset of symptoms before the age of 12 years.
Exclusion criteria
A subject is excluded from the study if he meets any of
the following criteria. He lacks capacity to give informed
consent; he has a moderate or severe learning disability,
defined as IQ < 60; he poses a serious risk of violence to
the researcher; he has current major depression, psych-
osis, mania or hypomania; he has a past history of bipo-
lar disorder or schizophrenia (we exclude those with a
clear history of episodic mania/hypomania or psychosis
unrelated to acute drug intoxication, but do not exclude
on the basis of chronic emotional dysregulation, i.e. irrit-
ability, frustration, anger or emotional-mood instability).
Subjects are also excluded if they have medical contrain-
dications to the use of stimulants (e.g. glaucoma, hyper-
tension, cardiovascular disease or a structural heart
problem); have been taking contraindicated medications
during the 4 weeks prior to randomisation; show drug-
seeking behaviour or craving (defined as drug-seeking
behaviour that is unusually severe and likely to affect the
titration protocol due to unusual and excessive demands
for drugs or where there is a current withdrawal syn-
drome from an addiction disorder with drug depend-
ency); receive any ADHD medication between consent
for screening and randomisation.
Trial medication
OROS-MPH (Concerta XL) is supplied as 18-mg capsules
and placebo to match. Capsules are over-encapsulated and
packaged in bottles of 46. Each bottle is assigned a unique
randomisation number; the randomisation system allocates
the right bottle to each patient. Over-encapsulation has
been successfully adopted in previous studies to generate
matched placebo to OROS-MPH. Piramal Healthcare UK
Ltd. supply the investigational medicinal product (IMP),
placebo to match manufacture, clinical trials packaging,
Qualified Person (QP) Certification and distribution for 200
patients. The Sponsor arranged the supply of Concerta 18-
mg tablets from the Marketing Authorisation Holder,
Janssen-Cilag Limited. Janssen-Cilag Limited provides the
summary of product characteristics (SmPC), updated
throughout the duration of the study.
The over-encapsulated active tablets are repacked in
high-density polyethylene (HDPE) bottles and exceed
the remaining shelf life of the study without the need for
a stability programme, as Concerta 18 mg has a
Marketing Authorisation for both HDPE and blister
packaging. Placebo tablets are manufactured once. Trial
medication over-encapsulation and packaging is under-
taken in two campaigns in order to accommodate a trial
duration of up to 3.5 years. Concerta 18-mg tablets typ-
ically have a maximum shelf life of 3 years from the date
of manufacture; however, by the time the product is
repacked for the clinical trial, the remaining shelf life is
likely to be under 2.5 years.
Over-encapsulation uses ‘DBcaps’ capsules which are de-
signed specifically for the blinding of clinical trial medica-
tions. We have to over-encapsulate Concerta and placebo
capsules with lactose capsules, rather than make a matching
placebo capsule, because Concerta capsules have printing
on them and are of a distinct shape that would be difficult
to manufacture and might infringe copyright. We sought
advice on this from previous investigators using OROS-
MPH and from companies that provide drug and placebo
supplies for studies. Studies on the use of DBcaps have
shown that over-encapsulation of capsules results in a lag
time of 2–3min in disintegration compared with the unen-
capsulated capsules. The pharmacokinetic properties of
Concerta XL 18-mg prolonged release capsules indicate re-
lease over several hours: following oral administration of
Concerta XL to adults the drug overcoat dissolves, provid-
ing an initial maximum drug concentration at about 1–2 h.
The MPH contained in the two internal drug layers is grad-
ually released over the next several hours. Peak plasma con-
centrations are achieved at about 6–8 h, after which plasma
levels of MPH gradually decrease (Section 5.2 of the Sum-
mary of Product Charateritics: https://www.medicines.org.
uk/emc/product/6872/smpv).
Prescribing and titration procedures
Trial medication is delivered as prescribed daily, with
participants observed to ensure they swallow the cap-
sules. There is a daily record of compliance with the trial
prescription. Both active medication and placebo are ti-
trated in the same way. Treatment starts at an initial
dose of 18 mg (1 tablet) for 1 week and is then increased
weekly over the following 4 weeks, in increments of 18
mg, to a maximum of 72 mg (4 tablets). Medication is
reduced by 18 mg (1 tablet) if there is a limiting adverse
event, in which case there will be no further increase in
medication for the duration of the trial. Medication may
be provided either once or twice daily up to the max-
imum daily dose. Titration upwards will be stopped if all
18 ADHD symptoms are scored as negligible (score of 0
or 1 on the CAARS) or absent. Unacceptable levels of
adverse effects on the lowest dose of 18 mg might lead
to a cessation of treatment in a few cases.
A maximum dose of 72mg was included for this trial
because previous clinical trials indicated that a proportion
of adults respond better at higher doses without
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unacceptable levels of adverse events, and because current
licensing for Concerta XL up to 54mg is based on dose
levels for children and adolescents, rather than adults.
NICE recommends a daily dose of MPH in adults to a
maximum of 100mg per day [7], and for Concerta XL the
British National Formulary (No 62, September 2011) rec-
ommends doses up to a maximum of 108mg in adults.
Strategies to improve adherence
We envisaged that adherence with allocated medication
will present a challenge for around 20% of participants.
Some offenders may not feel motivated to take the trial
medication if they experience adverse effects or do not
feel they are improving. They may also take medication
intermittently because of the strict prison regime that al-
lows for only a short time window for leaving their cells
to obtain medication from the medicine hatch on the
prison wings. The cases involving these persons are not
expected to contribute to missing data. In our pilot
study we accrued considerable experience in managing
the expectations of offenders and providing the support
needed to help participants adhere to the trial protocol.
The following steps will be adopted to maximise adher-
ence to medication:
1. In the pilot, minor adverse effects (13%) were the
most common reason for non-adherence to
medication. This was linked to the observation that
this population may be more sensitive to minor
adverse effects, particularly changes in appetite, than
community populations, perhaps reflecting the
importance of meal times to prisoners. To maximise
adherence to the protocol and minimise this as a
potential source of missing data, we will take care to
identify the early signs of minor adverse effects such
as appetite loss and adjust the medication dose
accordingly.
2. Seven percent of the pilot sample did not wish to
take medication in the mornings (08:00), which was
the initial protocol followed in the pilot study. We
then adjusted the protocol to allow for 12:00
medication for those who got up later in the day,
worked mainly in the afternoons or had a strong
preference for a 12:00 dosing, which resolved the
problem. This flexibility in dosing time more
accurately reflects dosing decisions in the
community and provides a better match to patients’
daily routines.
3. During the pilot study, prison staff did not always
let patients out of their cells to receive medication
or remind participants to get up on time. To
resolve this problem, we initiated the use of
research staff whenever possible to assist in the
delivery of medication by checking that prisoners
were always out of their cells on time to receive
trial medication.
4. In the pilot study, treatment was disrupted for the
Ramadan festival for several participants. We will
take care to check that participants are not started
on trial medication where religious customs might
interfere with adherence to the trial protocol.
5. In the pilot study, daily adherence to the trial
medication reduced when participants were not
reviewed weekly. One of the findings in the pilot
study was the importance that prisoners gave to the
weekly follow-up meetings when they can discuss
their ADHD and response to the treatment process,
in addition to completing study assessments. We
will therefore offer weekly meetings with offenders
throughout the 8-week trial.
6. Nurse support in addition to a research assistant
and medical staff will ensure that offenders are
given the support they need to adhere to the
protocol.
Concomitant treatments
Concomitant treatments are allowed with medications
that are not contraindicated with MPH. All concomitant
medications are recorded in the study database. Use of
the following medications in the 4 weeks prior to the
start of treatment with Concerta XL will lead to exclu-
sion from the clinical trial, based on potential adverse
drug interactions: clonidine, coumarins, monoamine oxi-
dase inhibitors, moclobemide and rasagline.
Baseline and outcome measures
The schedule of baseline and outcome measures as well as
the procedures for the trial are listed in Table 1. Baseline-
only measures are collected on all participants prior to
randomisation and include descriptors of the study popu-
lation and baseline moderators for further analysis as pre-
dictors of the treatment response. Primary and secondary
outcome measures are collected at baseline prior to ran-
domisation and 8 weeks after the initial trial prescription.
The primary outcome is the investigator-rated Conners
Adult ADHD Rating Scale (CAARS-O) at the 8 weeks
outcome. The other 5-week and 8-week measures are sec-
ondary outcomes or mediator variables. All outcome mea-
sures are listed in Table 2 along with their definitions.
Investigator-rated measuresThe following investigator-
rated meaures are used in the study:
 DIVA v2.0: DSM-IV-based Diagnostic Interview for
ADHD in Adults [23]. DIVA 2.0. is a semi-
structured interview assessment used to capture the
diagnostic symptoms and criteria for DSM-IV
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ADHD. The diagnostic algorithm applied to
these data was modified for DSM-5 criteria.
 MINI 7.0.1: Mini International Neuropsychiatric
Interview for comorbid mental health disorders
[24]. MINI 7.0.1 is a semi-structured interview
assessment used to capture DSM-IV diagnostic
criteria for common mental health disorders.
Sections completed included the following: major
depressive episode, suicidality, manic episode,
hypomanic episode, panic disorder, agoraphobia,
social anxiety disorder, obsessive-compulsive
disorder, post-traumatic stress disorder, psychotic
disorder and mood disorder with psychotic
features, generalised anxiety disorder, antisocial
personality disorder. In addition to diagnostic
categories evaluated at baseline only, we collected
cross-disorder symptom checklist scores at base-
line and at the 8 weeks assessments.
 ZAN-BPD: Zanarini Rating Scale for Borderline
Personality Disorder [25]. A validated scale for the
assessment of borderline personality disorder, used
as a baseline moderator variable.
 CAARS-O: Conners Adult ADHD Rating Scale for
ADHD symptoms [26]. The 8 weeks CAARS-O
assessment is the primary outcome measure for this
study. CAARS-O was also used as a secondary outcome
at week 5 and to assist the psychiatrist in titrating
participants onto the optimal trial medication dose.
CAARS-O consists of the 18 DSM-IV ADHD
symptoms, rated on a 4-point Likert scale (0 not at all,
never; 1 just a little, once in a while; 2 pretty often; 3
very much, frequently). This scale and other closely
Table 2 Primary and secondary outcome measures
Concept Instrument Time points for
analysis model
Type of measure Summary
measure
ADHD symptoms Conners Adult ADHD rating
scale (CAARS), investigator rated
M (B, 4, 5, 8) Continuous scale Mean difference
Emotional dysregulation Wender-Reimherr Adult ADHD
Diagnostic Scale (WRAADS),
investigator rated
M (B, 5, 8) Continuous scale Mean difference
Irritability Affective Reactivity Index (ARI),
self-rated
M (B, 5, 8) Continuous scale Mean difference
Spontaneous mind wandering Mind Excessively Wandering
Scale (MEWS), self-rated
M (B, 5, 8) Continuous scale Mean difference
Attitudes towards violence Maudsley Violence
Questionnaire (MVQ), self-rated
M (B, 5, 8) Continuous scale Mean difference
Common psychopathological symptoms Brief Symptom Inventory (BSI),
self-rated
M (B, 5, 8) Continuous scale Mean difference
Global impression of disease severity Clinical Global Impression (CGI)
scale, clinician rated
M (B, 5, 8) Categorical Mean difference
Behavioural problems recorded by prison officers in prison
records
Number of critical incidents
recorded in prison records
Incident rate
(B, 8)
Incident rate over
8-week period
Incidence rate
ratio
Prison office ratings of aggressive behaviour Modified Overt Aggression Scale
(MOASP), Prison Officer report
M (B, 8) Continuous Mean difference
Educational staff ratings of aggressive behaviour Modified Overt Aggression Scale
(MOASE), Education Staff report
M (B, 8)a Continuous Mean difference
Prison officer ratings of behaviour Behaviour Report Card (BRCP),
Prison Officer report
M (B, 8) Continuous Mean difference
Educational ratings of behaviour Behaviour Report Card (BRCE),
Educational Staff report
M (B, 8)a Continuous Mean difference
Engagement with the educational programme Number of educational sessions
attended over 8-week period
Incident rate
(B, 8)a
Incident rate over
8-week period
Incidence rate
ratio
Incentive points for rewarding behaviour Number of Incentives and
Earned Privileges (IEPs)
Incident rate
(B, 8)
Incident rate over
8-week period
Incidence rate
ratio
Current psychological distress CORE Outcome Measure
(CORE-OM), self-rated
M (8) Continuous Mean difference
Notes on time points for analysis:
M refers to modelling mean 8-week outcomes
Numbers in brackets refer to the assessment time points of measures included in the model (B = baseline, 4 = week-4 data, 5 = week-5 data, 8 = week-8 data)
For incident rate variables (e.g. number of behavioural problem reports) the baseline data are from the 8 weeks prior to randomisation; for the 8-week outcome
the data are from the 8-week period from the start of medication
aIndicates a measure completed for the subset of participants participating in education and related activities
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similar scales have been extensively validated as outcome
measures in previous clinical trials of adult ADHD.
 WRAADS: Emotional dysregulation measured from
the Wender-Reimherr Adult ADHD Diagnostic
Scale [27]. We applied the emotional dysregulation
items from an interview assessment of the
WRAADS-ED, following previous publications on
the treatment response of emotional symptoms in
ADHD [20, 28].
 AES: Adverse Events Scale [29]. Scale of common
adverse effects associated with stimulant
medications for ADHD used with permission from
the CADDRA website.
 CGI: Clinical Global Impression scale [30]. Scale used
by the research psychiatrist to give an overall rating of
clinical severity and a clinical impression of the clinical
response and adverse effects of the trial medication.
Participant self-rating scales
Self-rating scales are given to the participants for self-
completion. The scale questions are usually read out to
participants who give their response accordingly. The
self-rating scales are:
 Reactive-Proactive Aggression Questionnaire
(RPAQ) [31]. This scale is included as a baseline
moderator capturing proactive and reactive forms of
aggression.
 Weiss CD: Weiss conduct disorder scale. This scale
is included to capture conduct disorder symptoms
as a baseline moderator.
 Alcohol Use Disorders Identification Test (AUDIT-C)
and National Institute on Drug Abuse (NIDA) quick
screen. Alcohol and substance abuse checklist using
the AUDIT-C and NIDA quick screen to capture
drug and alcohol use in year prior to the current
prison sentence. The NIDA quick screen was adapted
from the single-question screen for drug use in
primary care by Saitz and colleagues [32]. AUDIT-C
is validated as a quick screen for alcohol use [33].
 Childhood Trauma Questionnaire (CTQ) [34].
Included as a potential moderator of the clinical
response to MPH.
 Barkley ADHD (B-ADHD). Self-rating scale for
DSM-IV ADHD symptoms [35] is as an initial
screening instrument. Participants are considered to
screen positive for ADHD if they have four or more
symptoms scoring 2 or more in either the
inattentive or hyperactive/impulsive symptom
domain.
 Affective Reactivity Index (ARI-S) [36]. A self-rating
scale for irritability.
 Mind Excessively Wandering Scale (MEWS) [37]. A
self-rating scale that captures excessive spontaneous
mind wandering, an aspect of psychopathology
that is closely associated with ADHD and a
strong predictor of ADHD-associated impairment
in daily life.
 Brief Symptom Inventory (BSI) [38]. A self-rating
scale that captures comorbid symptoms. Subscales
include nine symptom dimensions: somatisation,
obsession‐compulsion, interpersonal sensitivity,
depression, anxiety, hostility, phobic anxiety,
paranoid ideation, psychoticism.
 Maudsley Violence Questionnaire (MVQ) [39]. This
scale was designed to capture beliefs associated with
violence. The Machismo subscale relates to
embarrassment over backing down and justification of
violence in response to threat and attack; the
Acceptance subscale includes the overt enjoyment
and acceptance of violence in everyday life. In
previous research the Machismo subscale showed the
greater relationship to actual violence [39] and the
greater reduction in our pilot study for this trial [14].
 CORE Outcome Measure (CORE-OM) [40]. This
scale captures subjective well-being, problems and
symptoms, life functioning and risk and harm. It is
designed to measure psychological distress before
and after treatment.
Data from prison records and prison staff
Data will be collected from prison records and prison nurs-
ing and educational staff relating to behaviour in the 8
weeks before the collection of the baseline measures. For
cases of individuals new to custody presenting with signifi-
cant behavioural problems, the retrospective baseline report-
ing period will be for a period of 1 month or more, to allow
for initial behavioural problems that may arise when people
first enter prison. The data will include:
 Number of adjudications for antisocial behaviour
and rule breaking (HMP Isis and HMP/YOI
Polmont) and negative Incentives and Earned
Privileges (IEPs) (HMP Isis only)
 MOASP: Ratings of aggressive behaviour by Prison
Officers using the Modified Overt Aggression Scale
(MOAS) [41]
 BRCP: Ratings of behaviour by prison staff using
Behaviour Report Cards [42] by Prison Officers
 MOASE: Ratings of aggressive behaviour by
Education Staff using the MOAS. This item is
optional, depending on whether prisoners are
attending education sessions or not
 BRCE: Classroom Behaviour Report Card scored by
Education Staff (HMP Isis and HMP/YOI Isis). This
item is optional, depending on whether prisoners are
attending education sessions or not
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 IEPs: Number of positive IEPs for positive
engagement in education, occupational and
rehabilitation programmes (HMP Isis only).
Baseline measures
The following measures are recorded at baseline.
CAARS-O; WRAADS (three subscores: temper, affective
lability, emotional over-reactivity), weight, pulse, blood
pressure, Weiss CD, IQ (Wechsler Abbreviated Scale of
Intelligence [WASI]), DIVA score and ADHD diagnosis,
ZAN-BPD score, drug use in lifetime and alcohol use in
the past year, RPAQ (two subscales: reactive, proactive),
MEWS, CTQ, MVQ, CORE-OM, CGI, ARI-S, concomi-
tant medications, BSI, MINI 7.0.1 and AES.
Primary outcome measure
The primary endpoint is the level of ADHD symptoms
measured on the investigator-rated CAARS-O at 8 weeks
post-treatment initiation to address the question of effi-
cacy of OROS-MPH on ADHD symptoms in young of-
fenders meeting DSM-5 diagnostic criteria for ADHD.
Investigator-rated CAARS-O scores are a common out-
come measure used in previous treatment trials of
ADHD in the community; the CAARS-O score measures
the same list of 18 symptoms used as the primary out-
come in nearly all other studies of adult ADHD.
Secondary outcome measures
Secondary outcomes address important questions about
the effects on comorbid symptoms and behavioural im-
pairments that are commonly seen in offenders with
ADHD. These are critical incidents (adjudications) from
prison records for the 8-week period (in two 4-week pe-
riods) from initiation of the trial medication to the 8
weeks assessments; ratings of aggressive behaviour by
prison staff using the MOASP at 8 weeks; BRCP behav-
iour report cards from prison staff at 8 weeks; engage-
ment with educational activities (including number of
scheduled educational sessions, proportion of scheduled
educational sessions attended and reports of disruptive
behaviour in education session reported at 8 weeks using
the BRCE and MOASE completed by education staff—
only for those people involved in education); attitudes
towards violence using the MVQ at 8 weeks, CORE-OM
at 8 weeks; general psychopathology using the BSI at 8
weeks; excessive mind wandering measured using the
MEWS at 8 weeks; symptoms of emotional dysregulation
measured using the WRAADS at 8 weeks; symptoms of
emotional dysregulation measured using ARI at 8 weeks;
overall health measured using CGI at 8 weeks.
Mediator measures
To address the secondary mediation hypotheses, the fol-
lowing putative mediators are recorded at 5 weeks and
at baseline: CAARS-O hyperactive/impulsivity and in-
attention subscores and WRAADS for emotional dysreg-
ulation. These measures are hypothesised to mediate
treatment response in terms of secondary behavioural
outcomes (critical incidents and prison staff classroom
report cards). Critical incidents are taken from the
prison records at 8 weeks and are recorded over the pre-
vious 4 weeks. The prison staff classroom report cards
are recorded at 8 weeks and record behaviour over the
preceding week.
Participant timelines
A schedule of participant visits is illustrated in Fig. 2.
Consent
There are two stages of consent. Initial consent 1 (screen-
ing and diagnostic step) allows for the use of screening
questionnaires for ADHD, followed by a diagnostic assess-
ment using the DIVA interview for adult ADHD and re-
view by a trained psychiatrist. During these pre-trial steps,
patients who fail eligibility criteria will not be invited to
continue and will not be asked to provide consent 2, to
participate further in the trial (clinical trial step). The eligi-
bility criterion which they are identified as failing will be
noted. Individuals who do meet the diagnostic and eligibil-
ity criteria are invited to take part in the clinical trial, at
which stage informed consent is requested to take part in
the randomised controlled trial. Consent 2 is taken by the
trial psychiatrists.
Informed consent for the trial (consent 2) is obtained by
providing the participants with written information sheets
and ensuring that they understand the information pro-
vided and the implications of taking part in the research,
prior to obtaining signed consent (see Additional file 1 for
a copy of the information and consent forms). They are
offered the opportunity to be treated for ADHD as part of
the trial, or alternatively they are offered treatment outside
of the trial. The participants have as long as they like to
decide while the trial is ongoing.
Patients complete baseline measures after providing
informed consent to take part in the trial (consent 2).
Once the baseline assessments are complete and eligibil-
ity checks completed and documented, the individuals
will be randomised to one of the treatment arms.
Research visits
Following consent 1 for screening, and confirmation
of the diagnosis of ADHD and eligibility by a psych-
iatrist trained in the assessment of ADHD, informa-
tion sheets and consent forms for the controlled trial
(consent 2) will be provided and discussed with po-
tential participants (visit 1). Information sheets will be
reviewed and informed consent obtained for the clin-
ical trial (visit 2). There is no limit on the time taken
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between visits 1 and 2 within the timeframe of the
project. Potential participants will be encouraged to
take as much time as they need to reach a fully in-
formed decision about participation in the trial. Base-
line data will be collected from participants, prison
records and members of staff (visit 3). Once baseline
data have been collected and eligibility confirmed fol-
lowing medical review by a psychiatrist, participants
will be randomised to treatment with placebo or
OROS-MPH (visit 4). Trial prescriptions will be com-
pleted and given to the pharmacy. Medication should
start within 1 week of visit 4 (i.e. randomisation).
One week after the start of trial medication, the partic-
ipants are reviewed, and trial medication titrated accord-
ing to their clinical response and adverse effect profile
(visit 5, week-1 titration). Symptoms of ADHD are mea-
sured using the CAARS-O, adverse events checked using
the AES and blood pressure and pulse checked. This ti-
tration procedure is repeated at weeks 2–4 (visits 6–8).
Five weeks after the start of medication (visit 9, week-5
assessment) the prescription (the titrated dose) is con-
firmed and maintained for the rest of the trial. At the
week-5 assessment, outcome measures are completed by
a research investigator for the CAARS-O, WRAADS and
Fig. 2 Schematic diagram of flow of participants (potential and actual) through the pre-trial assessment and trial
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MEWS and the pulse, blood pressure, weight and AES.
The final visit 10 is completed 3 weeks later after 8
weeks from the first prescription of the trial medication.
At this visit all outcome measures are completed. As far
as possible the information on clinical response derived
during the titration visits (weeks 1–4) is not shared with
other members of the research team, particularly with
the investigator completing the weeks 5 and 8 outcome
measures. Thus, potential unblindings based on the ob-
served clinical response and adverse events will be
minimised.
Sample size calculations
The total sample size to be randomised is 200.
The primary outcome is ADHD symptoms, measured
using CAARS-O. The results of a single-arm open label
pilot study of young prisoners with ADHD who were
given MPH showed a mean decrease of 25.0 points with
a standard deviation of 9.1 [14]. This suggested a stan-
dardised effect size of SMD = 2.75. It could reasonably
be assumed that at least 20% of this effect might be at-
tributed to the effects of MPH. On this basis, this study
is powered to detect a standardised effect size of d =
0.55. Assuming a standard deviation of 9.1, this would
translate into a treatment difference of 5.0 points. This
effect size is consistent with the results of a recent meta-
regression analysis (12), which estimated the effect of
treatment to be SMD = 0.49 (95% CI 0.08, 0.64). The
sample size calculation used G*Power version 3 and was
based on the use of a t test to compare the means of the
treatment groups. In order to have 90% power at the 5%
significance level to detect a standardised effect of
SMD = 0.55, this study would need to collect outcome
data on 142 participants. Inflating for the expectation
that loss to follow-up may be as high as 25%, a mini-
mum of 190 participants should be recruited, with the
target for the study set at 200.
A 25% loss is expected to be easily achievable, since in
the pilot 10% left the prison due to unexpected transfers
from the prison, and problems with adherence to trial
medication were rarely followed by problems completing
trial assessments.
Recruitment procedures
Participants will be recruited from HMYOI Isis
(London) and HMYOI Polmont (Falkirk). Following
consent to be screened for ADHD (consent 1), screening
questionnaire data will be collected by the prison mental
health teams using a DSM-IV ADHD symptom rating
scale (25). Patients who screen positive will be invited to
complete the DIVA [27]. This will be followed by a clin-
ical review by a psychiatrist trained in the diagnostic as-
sessment of ADHD, including collateral information
obtained from an informant whenever feasible.
Following clinical review, patients who meet diagnostic
criteria for ADHD and the other eligibility criteria for
the trial will be invited to take part in the clinical trial.
Eligibility for the study will be further checked and re-
corded once the consent form (consent 2) has been
signed and baseline assessments have been completed,
prior to randomisation. Using an algorithm that applies
the DSM-5 criteria to the DIVA interview data, the po-
tential participants will be checked to ensure they meet
diagnostic criteria for DSM-5 ADHD. A clinical review
by a psychiatrist trained in the diagnostic assessment of
ADHD will review all inclusion and exclusion criteria.
The exclusion criteria of IQ less than 60 will be based
on the 95% CI for the IQ estimate from the WASI-II in-
cluding IQ of 60, in combination with a clinical assess-
ment by the psychiatrist to confirm that the participant
has the ability to understand the rating scale and inter-
view assessment questions; understand the information
sheet and the study procedures and risks; and the ability
to provide sufficiently detailed accounts of ADHD symp-
toms and behaviours, consistent with an IQ score
greater than 60. Since there are no validated IQ tests for
the visually impaired, including WASI-II, this criterion
will be based on clinical judgement alone for participants
with this impairment. This will also be the procedure for
anyone unable to complete the WASI-II assessment due
to severity of their ADHD symptoms or other mental
health problems.
Withdrawal of subjects
Participants have the right to withdraw from the
study at any time for any reason, and healthcare staff
have the right to withdraw patients from the trial if
they consider the trial is having an adverse effect on
the participants. However, where participants discon-
tinue taking trial medication, we will invite them to
remain in the study to complete trial assessments,
thereby minimising loss of data. Should a participant
decide to withdraw from the study, all efforts will be
made to report the reason for withdrawal as thor-
oughly as possible.
Due to potential concerns about the interaction of
trial medication with unknown psychoactive sub-
stances, if a participant discloses to any member of
the research team that he has used ’spice’, i.e. syn-
thetic cannabis or another unknown psychoactive sub-
stance, while participating in the study, a clinical
evaluation will be made. If it is current use (defined
as within the last 2 days), the study medication will
be stopped. If it happened earlier in the study and is
considered an isolated incident, the trial medication
can continue. If the trial medication is stopped, the
participant will remain in the study and will be asked
to complete trial assessments. A clinical assessment
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will be made on a case-by-case basis as to the safety
of restarting the trial medication after 48 h from the
time of stopping the trial medication.
Randomisation and allocation concealment
Randomisation to OROS-MPH or placebo will be at a
1:1 ratio. Randomisation is at the participant level
and is performed using the King’s Clinical Trials Unit
(CTU) independent Randomisation Service, ensuring
reliability and credibility in the randomisation process,
with blinding of both investigators and participants.
Randomisation is stratified by prison with variable
block sizes to ensure that equal numbers of patients
are allocated to the two arms within each prison
stratum. Patient characteristics will not be considered
in the randomisation process. However, we expect the
drug treatment and placebo trial arms to be balanced
in terms of cognitive ability, ADHD symptom severity
and co-occurring psychosocial and mental health
problems.
Prescriptions are completed by the trial psychiatrist.
Each patient is allocated a kit (labelled carton) contain-
ing four labelled bottles, each containing 46 active or
placebo tablets. Each kit and its bottles will be labelled
according to Annex 13 guidelines and have its own ran-
domisation/treatment pack number. The centralised ran-
domisation system will allocate the correct treatment
pack/kit to each patient during the trial.
Blinding
Blinding is maintained for all study investigators, in-
cluding the on-site researchers, pharmacy, statistical
and data management teams. Investigators will be un-
blinded after the primary analysis is complete. The
primary analysis dataset will not include any trial
medication dosage data to ensure that the statistician
remains blinded. We do however propose a sensitivity
analysis to assess efficacy for those complying with
tablets offered. This analysis will exclude those partic-
ipants who took no trial medication on less than 75%
of the days on which it was prescribed. Additionally,
persons who withdraw from treatment or the trial or
are released, transferred or deported will be excluded.
We will not consider what proportion of the pre-
scribed medication was taken on any given day.
We intend to use linear mixed modelling, which as-
sumes that only variables included in the model pre-
dict missingness. We will assess empirically whether
this particular missing at random (MAR) assumption
is reasonable, using an independent statistician to
maintain blinding if necessary. If the assumption is
not reasonable, multiple imputation will be used in-
stead to accommodate the missing data generating
process, and the statistician might need to become
unblinded at this point, but investigators will remain
blind until the primary analysis is complete. The In-
vestigator must report all code breaks (with reason)
as they occur on the case report form.
Emergency unblinding
Emergency unblinding will follow the standard operating
procedures for the King’s Health Partners Clinical Trials
Office (KHPCTO). In circumstances where unblinding is
deemed necessary, the starting point will always be the
local investigating team. Whenever possible the decision
to unblind will be made by the Chief Investigator, the
Principal Investigator or clinically qualified staff working
on the project. Out of hours, if clinically qualified mem-
bers of the research team are not available, then the 24-
h Emergency Scientific and Medical Services (ESMS)
system will be used. The ESMS system consists of a call
centre which is manned around the clock by information
scientists who have a minimum qualification of a life sci-
ence degree to include toxicology or pharmacology.
These information scientists are always available and are
the direct line of communication to the number on the
patient card. The information scientists will be trained
in the specific details of this study and have direct access
to one of the ESMS consultant physicians should clinical
advice be required. Our consultant physicians practice
general and internal medicine and specialise in clinical
pharmacology and toxicology, ensuring clinical advice is
available night and day. To maintain the overall quality
and legitimacy of the clinical trial, code breaks will occur
only in exceptional circumstances when knowledge of
the actual treatment is absolutely essential for further
management of the patient. The Investigator will always
maintain the blind as far as possible.
Statistical analyses
A detailed statistical analysis plan has been developed by
the trial statisticians in collaboration with the Chief Investi-
gator and approved by the Trial Steering Committee (TSC).
Analyses will be carried out by the trial statistician (RH)
and checked by the senior statistician co-investigator (SL).
In the first instance data will be analysed under
intention-to-treat assumptions; that is, participants will
be analysed in the groups to which they were rando-
mised irrespective of treatment received. Efficacy will be
assessed by comparing primary and secondary outcomes
between the OROS-MPH and placebo arms.
In order to assess the efficacy of the continuous primary
CAARS-O outcome (see Table 2), a linear mixed model
will be used. The model will contain CAARS-O scores
from the last three (4, 5 and 8 weeks) post-randomisation
time points as the dependent variable and baseline
CAARS-O values, randomisation stratifier (prison), trial
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arm, dummy variables coding assessment time point (4, 5
or 8 weeks) and trial arm x time point interaction terms as
explanatory variables. Random effects that vary at the par-
ticipant level will be used to model the covariance struc-
ture between the repeated measures. The approach will
ensure that a different trial arm effect can be estimated at
4, 5 or 8 weeks—with the estimated effect at 8 weeks pro-
viding the evaluation of OROS-MPH efficacy in terms of
the primary outcome. Similar models will be used to
evaluate continuous secondary outcomes.
The secondary count outcomes at 8 weeks (e.g. number
of critical incidents) will be compared between treatment
arms using Poisson regressions to estimate incidence rate
ratios (after conditioning on baseline counts and random-
isation stratifiers). Logistic regression will be carried out
for scheduled educational sessions attended. Parameters
will be estimated using maximum likelihood.
Inferences will remain valid in the presence of missing
data provided that the missing data generating mechan-
ism is MAR. More specifically, this particular MAR as-
sumption stipulates that only variables included in the
analysis model drive missingness. While we model sev-
eral time points simultaneously, inferences will be made
only at the time point of interest (8 weeks). Using linear
mixed models means that we can allow variables mea-
sured and included in the model (e.g. previously ob-
served values of the outcome including baseline values,
trial arm, stratifier and post-treatment time point) to
predict attrition, and allows us to make use of all avail-
able data. We will also check empirically whether with-
drawal from allocated treatments is predictive of missingness
at 8weeks. And if we find that such post-randomisation vari-
ables drive missingness, we will consider using multiple im-
putation to accommodate such a MAR process. Mediation
analysis using structural equation modelling will be used to
partition the total treatment effect into mediated and non-
mediated components.
Discussion
Accountability for trial medication
All aspects of treatment and accountability for managing
the medication storage and delivery are managed locally
by the prison pharmacies and mental health teams, as per
standard practice for this medication in the prisons. Inves-
tigational medicinal product (IMP) accountability will be
recorded and verified. All aspects of treatment compliance
and recording of treatment administration/refusal are
managed by the prison mental health teams and locally by
healthcare staff as per standard practice for these sites. Pa-
tients are observed when they are given medication and
checked to ensure the capsules have been swallowed. This
information is then recorded (signed off) by nursing staff
who delivered the medication on prison pharmacy record
sheets or digital records.
Safety checks
Patients are monitored daily by the prison mental and
healthcare teams. Safety checks will be conducted in line
with NICE Guidelines (2009).
Regarding the research aspect of the study (i.e. obtain-
ing follow-up data), there is little risk to participant
safety. Participants will be aware that should they wish
to withdraw from the study they may do so. Participants
who become upset or distressed by the questions in the
research (this is unlikely, as the questions are similar to
those asked regularly in the context of their clinical care)
will be offered support by the researchers and by the
prison mental health team.
The healthcare team will follow national guidelines on
safety, which is predominantly related to monitoring of
cardiovascular function. More specifically, the clinical
care will follow these procedures:
1. Before commencing treatments, checks will be
made on pulse and blood pressure and review of
healthcare records.
2. Potential cardiovascular abnormalities will be
evaluated for risk and, if necessary, an opinion will
be obtained from a cardiologist prior to
commencing treatment.
3. The clinical team will check pulse and blood
pressure once a week for the first 5 weeks and at
the end of the 8-week trial.
Other safety checks will include monitoring of adverse
events during assessments. In addition, participants will
be monitored daily by prison staff, and any potential ad-
verse events will be reported to the prison healthcare
team.
Procedures for recording and reporting adverse events
Safety will remain the responsibility of the prison mental
healthcare team. Adverse events of any medical or non-
medical intervention identified or recorded by the re-
search team at each site will be verified by the clinician
who is part of the research team, or by an assigned med-
ical colleague at specialist registrar grade or above who is
a member of the prison healthcare team or by the clinical
lead for the project (Professor Asherson). The decision to
stop treatment following an adverse event will remain the
responsibility of the clinical team. Minor adverse events
that do not come under official reporting procedures will
be reported to the clinical team, e.g. sleep disturbance,
minor levels of anxiety or dysthymia, small increase in
pulse and blood pressures, reduced appetite and other
minor physical symptoms that do not endanger patients
or cause more than minor distress. All other adverse
events from medication will be recorded and reported in
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line with The Medicines for Human Use (Clinical Trials)
Regulations 2004 and Amended Regulations 2006.
The research team acting on behalf of King’s College
London as Sponsors have delegated the delivery of the
Sponsor’s responsibility for Pharmacovigilance, as de-
fined in Regulation 5 of the Medicines for Human Use
(Clinical Trials) Regulations 2004, to the KHPCTO.
Reporting of serious adverse events (SAEs) will continue
until the last patient last dose has been completed. For
each participant, the reporting period will be from the
time of first dose of the trial medication to the end of
his involvement in the trial (last dose at the end of 8
weeks). All SAEs, serious adverse reactions (SARs), sus-
pected unexpected serious adverse reactions (SUSARs)
and Important Medical Events (IMEs) (excepting those
specified in this protocol as not requiring reporting) will
be reported immediately by the Chief Investigator or
designated site investigators to the KHPCTO in accord-
ance with the current Pharmacovigilance Policy. We will
copy this information to Janssen-Cilag at the same time.
The KHPCTO will report SUSARs and other SARs to
the Medicines and Healthcare products Regulatory
Agency (MHRA) and competent authorities of other
European Economic Area (EEA) states in which the trial
is taking place.
The Chief Investigator will report to the relevant eth-
ics committees. Reporting timelines are as follows:
 SUSARs which are fatal or life-threatening must be
reported not later than 7 days after the Sponsor is
first aware of the reaction. Any additional relevant
information must be reported within a further 8
days.
 SUSARs that are not fatal or life-threatening must
be reported within 15 days of the Sponsor first
becoming aware of the reaction.
The Chief Investigator and KHPCTO (on behalf of the
Co-Sponsors) will submit a Development Safety Update
Report (DSUR), relating to this trial IMP, to the MHRA
and Ethics Committee annually.
Treatment stopping rules
The trial may be prematurely discontinued by the
Sponsor, Chief Investigator or Regulatory Authority on
the basis of new safety information or for other reasons
given by the Data Monitoring and Ethics Committee
(DMEC)/TSC, Regulatory Authority or Ethics Commit-
tee concerned. Trial discontinuation for safety reasons is
not envisaged given the successful pilot study. If the
study is prematurely discontinued, active participants
will be informed and no further participant data will be
collected.
Trial Steering Committee
A TSC will be convened to provide overall supervision
of the trial and ensure the trial is conducted to the rigor-
ous standards set out in the Medical Research Council
(MRC) guidelines for Good Clinical Practice (GCP). The
TSC will monitor progress, adherence and safety. The
TSC chair is Professor Jenny Shaw (Consultant Forensic
Psychiatrist, University of Manchester), and members in-
clude Dr. Ylva Ginsberg (Consultant Psychiatrist specia-
lising in ADHD in prisoners, Stockholm, Sweden), Peter
Mason (Forensic Psychiatrist and specialist in ADHD,
Cheshire and Wirral), Anthony Davis, R&D Manager
(Oxleas National Health Service [NHS] Foundation
Trust), Dr. Ulrich Muller-Sedgwick (Barnet, Enfield and
Haringey Mental Health NHS Trust) and Beverley
Nolker, (POA learning and user representative). Non-
independent members are the lead applicants in London
and Edinburgh (Philip Asherson and Lindsay Thomson).
Other members of the research management group will
attend as observers and to report to the TSC. It is envis-
aged that the TSC will meet before the start of the pro-
ject and every 6 months, alternating between telephone
conference and face-to-face meetings.
Data Monitoring and Ethics Committee (DMEC)
A DMEC will be convened to monitor the safety, efficacy,
ethical conduct and quality of the data. The committee
will consist of three members experienced in clinical trials,
including an independent statistician. The DMEC chair is
Professor Seena Fazel, University of Oxford (an experi-
enced Forensic Psychiatrist). Other members are Professor
Chris Hollis, University of Nottingham (an expert on the
Clinical Management of ADHD) and Adrian Cook (a trial
statistician). DMEC meetings will be timed to occur prior
to TSC meetings for timely reporting to the TSC. A sum-
mary of the role and reporting structure is available from
the Chief Investigator on request.
Local trial management
The project will be led by Professor Asherson (PA) in
London supported by a Trial Manager. The Trial Man-
ager will liaise with the trial monitors and ethical board
where required and support completion of interim re-
ports as well as the ongoing management of the project.
The Research Psychiatrist at YOI Isis will coordinate all
daily activities on site. Principal Investigator Thomson
(LT) will lead the project in Edinburgh and will be sup-
ported by the local RA, who will conduct similar day-to-
day coordinating tasks in HMYOI Polmont.
Project Management Group
The project will be led by Chief Investigator Asherson
in London. The programme manager in London will
liaise with the Edinburgh study coordinator weekly
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throughout the project, monitor progress and maintain
communication about successes and barriers to progress
and report back to the lead applicants. Asherson and
Thomson will hold a weekly telephone conference to re-
view progress with the data collection teams. A meeting
of all investigators and co-applicants will review progress
on a monthly basis.
Ethical issues specific to this project
The trial will be conducted in compliance with the prin-
ciples of the Declaration of Helsinki (1996), the princi-
ples of GCP and in accordance with all applicable
regulatory requirements including but not limited to the
Research Governance Framework and the Medicines for
Human Use (Clinical Trial) Regulations 2004, as
amended in 2006 and any subsequent amendments. This
protocol and related documents will be submitted for re-
view to London South East Research Ethics Committee
(REC), and to the MHRA for Clinical Trial Authorisa-
tion. Annual progress and safety reports and a final re-
port at conclusion of the trial will be submitted to the
KHPCTO (on behalf of the Sponsor), the REC and the
MHRA within the timelines defined in the regulations.
We previously received ethical approval and MHRA
registration for the current open label trial of OROS-
MPH in HMP Isis and will follow the same recruitment
and consent procedures as in the previous study.
OROS-MPH is only licensed for first-time use in young
people with ADHD and severe impairment under the age of
18, although NICE also recommends MPH as the first-line
treatment for ADHD in adults. The 8-week trial includes a
placebo group, so we will be denying a recommended treat-
ment for ADHD during this period. However, currently
prisoners with ADHD are rarely treated because of uncer-
tainty over validity of the ADHD diagnosis, efficacy of treat-
ment and concerns about potential drug abuse and
diversion in prison populations. To address the issue of
equal access to treatment, we will offer treatment to all par-
ticipants once the trial is completed. Care will be taken to
ensure that no coercion is involved in recruiting prisoners
into the study. Initial consent will be obtained by members
of the prison mental health team. Following procedures in
the pilot study, informed consent will be obtained at the
screening and diagnostic steps as well as at the start of the
trial. All participants will have the mental capacity to make
informed decisions. It will be made very clear that taking
part in the study will have no impact, negative or positive,
on their time in the prison or the prison regime. However,
some participants may benefit (and show improvements in
behaviour) from the treatment that is offered as part of the
clinical trial. Taking part in the study will not lead to loss of
earnings. The study medication is a controlled substance.
There are however standard operating procedures in place
for the prescription of controlled drugs from the prison
pharmacy.
Participants are informed that their anonymised re-
search data from this study will be stored securely and
may be shared with other scientists or research groups
where this helps us to understand the findings of the
study. The data may also be used in combination with
data from other similar studies.
All personal information is stored in a secure place
(locked cabinet in locked office in the prisons). Outside
of the immediate healthcare team involved in this re-
search, no one will be able to match personal informa-
tion (name and prison number) with the information
gathered for research. After completion of the study,
personal information held by the local study teams will
be destroyed. Personal details will only be used to con-
tact participants about the study. Personal details will
not be linked to clinical or prison records in the research
records. The clinical data and prison records used for re-
search will be identified using a study ID code.
Quality assurance
Monitoring of this trial will be to ensure compliance
with GCP, and scientific integrity will be managed and
oversight retained by the KHPCTO Quality Team.
Data handling
The Chief Investigator (PA) will act as custodian for the
trial data. Data will be stored on a database to be set up by
the Clinical Trials Unit (CTU) at King’s College London.
Patient data will be pseudo-anonymised. All pseudo-
anonymised data will be stored on a password-protected
computer. All trial data will be stored, handled, processed
and archived in line with the Data Protection Act and the
Medicines for Human Use (Clinical Trials) Amended Reg-
ulations 2006.
Data management
Data will be stored on a trials database to be set up by the
CTU at King’s College London. This allows for full audit
information and checks on data entry that will be used to
ensure the integrity of the data collection and monitoring
of the study progress. At the end of the study, all research
records will be transferred by secure courier service to the
Social, Genetic and Developmental Psychiatry (SGDP)
Centre, King’s College London. A detailed data manage-
ment plan is available from the authors.
Publication policy and access to data
It is intended that the results of the study will be reported
and disseminated at international conferences and in
peer-reviewed scientific journals. Additionally, we will dis-
seminate through internal reports to the prison services
and through relevant online forums such as the UK Adult
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ADHD Network (UKAAN). The data collected will be
shared and used in collaborative studies once the main ob-
jectives of the study have been completed. We will provide
efficient and rapid access to data to scientists following a
formal review process by the study co-investigators. The
dataset that will be shared will be anonymised, meaning
that it will not include data of name, birthdate or prisoner
record number. Any raw data from the trials database or
randomisation system will not be shared. Investigators
who wish to access the data once the study is finished
should contact the Chief Investigator (PA) and request
permission. A formal application will be required indicat-
ing the question to be addressed and methods to be ap-
plied. Data access will be allowed for all legitimate
scientific enquiries following scientific review by the Chief
Investigator and co-applicants.
Over the duration of the study, many people will have
contributed to the CIAO-II project. We will follow the
principles outlined in the International Committee of
Medical Journal Editors Recommendations for the Con-
duct, Reporting, Editing, and Publication of Scholarly
Work in Medical Journals (ICMJE Recommendations
2013).
These four criteria are reproduced as follows:
1. Substantial contributions to the conception or
design of the work; or the acquisition, analysis, or
interpretation of data for the work; AND
2. Drafting the work or revising it critically for
important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the
work in ensuring that questions related to the
accuracy or integrity of any part of the work are
appropriately investigated and resolved.
In addition to being accountable for the parts of the
work he or she has done, an author should be able to
identify which co-authors are responsible for other spe-
cific parts of the work. In addition, authors should have
confidence in the integrity of the contributions of their
co-authors.
Insurance/indemnity
Clinical Trial insurance is provided by the King’s College
London Clinical Trials Insurance Policy.
Trial status
The protocol version is version v2.0, 30 August 2018.
Recruitment started 30 May 2016. Recruitment was
completed on 30 May 2019. Last particpant last visit 6
June 2019. Data lock 27 August 2019.
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